Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541536 | 0.89 | PLA2G7 (0.53) | PTGDR2KMT2AMEN1PLA2G7LMNA | |
| SCHEMBL4416151 | 0.74 | PLA2G7 (0.64) | PLA2G7 | |
| SCHEMBL3534354 | 0.72 | PLA2G7 (0.58) | KMT2AMEN1PLA2G7 | |
| SCHEMBL11344317 | 0.71 | ALDH1A1 (0.46) | SMN1; SMN2KMT2AMEN1PLA2G7LMNA | |
| SCHEMBL3538750 | 0.70 | PLA2G7 (0.57) | PLA2G7 | |
| SCHEMBL5120452 | 0.69 | PTGDR2 (1.00) | PTGDR2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3538417 | 0.69 | PLA2G7 (0.55) | PLA2G7 | |
| SCHEMBL3534790 | 0.69 | PLA2G7 (0.55) | PLA2G7 | |
| SCHEMBL3612929 | 0.69 | PLA2G7 (0.58) | PLA2G7 | |
| SCHEMBL4427022 | 0.69 | PLA2G7 (0.65) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165365-A1 | Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same | ARTZYME BIOTECH CORPORATION (KR) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165365-A1 | Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same | CPN1, RNPEP, ANPEP | PTGDR2 4576/4885RAB9A 2227/4885SMN1; SMN2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.